Literature DB >> 1732965

Carotid artery disease: evaluation with acetazolamide-enhanced Tc-99m HMPAO SPECT.

R W Burt1, R M Witt, D F Cikrit, R V Reddy.   

Abstract

Sixty patients were studied for carotid artery disease and were further evaluated with hexamethyl-propyleneamine oxime (HMPAO) single photon emission computed tomography (SPECT) both at baseline (with the patient resting) and after administration of acetazolamide (ACZ). Of these 60 patients, 58 (97%) had symptoms and 49 (82%) had stenoses greater than 70% in at least one internal carotid vessel. Nine patients (15%) had symmetric findings on baseline examinations and at SPECT with ACZ. Thirty-two patients (53%) had asymmetric findings on baseline, but in 24 of these patients (75%) additional lesions were observed after ACZ administration. Nineteen patients (32%) had asymmetric findings only after ACZ was administered. HMPAO SPECT with ACZ allows detection of diminished cerebral perfusion reserve that is not found when HMPAO SPECT is performed with the patient at rest. This procedure helps provide an objective evaluation of the hemodynamic effects of carotid stenosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732965     DOI: 10.1148/radiology.182.2.1732965

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Is image subtraction necessary in the clinical interpretation of single-day split-dose stress cerebral perfusion single-photon emission tomography using technetium-99m compounds?

Authors:  C O Wong; W J MacIntyre; E Q Chen; G B Saha; D Chyatte; R T Go
Journal:  Eur J Nucl Med       Date:  1996-10

Review 2.  New diagnostic tests combining drugs and nuclear medicine.

Authors:  R W Myers
Journal:  West J Med       Date:  1994-10

3.  Simultaneous multi-slice (SMS) acquisition enhances the sensitivity of hemodynamic mapping using gas challenges.

Authors:  Harshan Ravi; Peiying Liu; Shin-Lei Peng; Hanli Liu; Hanzhang Lu
Journal:  NMR Biomed       Date:  2016-09-06       Impact factor: 4.044

4.  A study of acetazolamide-induced changes in cerebral blood flow using 99mTc HMPAO SPECT in patients with cerebrovascular disease.

Authors:  S Asenbaum; A Reinprecht; T Brücke; S Wenger; I Podreka; L Deecke
Journal:  Neuroradiology       Date:  1995-01       Impact factor: 2.804

5.  Contrast-enhanced 2D cine phase MR angiography for measurement of basilar artery blood flow in posterior circulation ischemia.

Authors:  Takeshi Kato; Toshikatsu Indo; Eiji Yoshida; Yasushi Iwasaki; Mie Sone; Gen Sobue
Journal:  AJNR Am J Neuroradiol       Date:  2002-09       Impact factor: 3.825

6.  Qualitative versus quantitative assessment of cerebrovascular reactivity to acetazolamide using iodine-123-N-isopropyl-p-iodoamphetamine SPECT in patients with unilateral major cerebral artery occlusive disease.

Authors:  Kuniaki Ogasawara; Taku Okuguchi; Masayuki Sasoh; Masakazu Kobayashi; Hirotsugu Yukawa; Kazunori Terasaki; Takashi Inoue; Akira Ogawa
Journal:  AJNR Am J Neuroradiol       Date:  2003 Jun-Jul       Impact factor: 3.825

7.  18FDG PET and acetazolamide-enhanced 99mTc-HMPAO SPET in systemic lupus erythematosus.

Authors:  F Grünwald; A Schomburg; A Badali; J Ruhlmann; L Pavics; H J Biersack
Journal:  Eur J Nucl Med       Date:  1995-09

8.  Cerebrovascular Reservoir and Arterial Transit Time Changes Assessed by Acetazolamide-Challenged Multi-Phase Arterial Spin Labeling Perfusion MRI in Chronic Cerebrovascular Steno-Occlusive Disease.

Authors:  Inpyeong Hwang; Chul-Ho Sohn; Keun-Hwa Jung; Eung Koo Yeon; Ji Ye Lee; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Seung Hong Choi; Ji-Hoon Kim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-01-29

9.  Acetazolamide-augmented dynamic BOLD (aczBOLD) imaging for assessing cerebrovascular reactivity in chronic steno-occlusive disease of the anterior circulation: An initial experience.

Authors:  Junjie Wu; Seena Dehkharghani; Fadi Nahab; Deqiang Qiu
Journal:  Neuroimage Clin       Date:  2016-11-17       Impact factor: 4.881

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.